Prospera Financial Services Inc Tcr2 Therapeutics Inc. Transaction History

Prospera Financial Services Inc

  • $3.82 Billion
  • Q3 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 08, 2022
SELL
$2.11 - $2.94 $211 - $294
-100 Closed
0 $0
Q1 2022

May 04, 2022
BUY
$2.4 - $4.71 $240 - $471
100 New
100 $0

About TCR2 THERAPEUTICS INC.

TCRR Quotes by TradingView
  • Ticker TCRR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,606,400
  • Description
  • TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...
More about TCRR
Track This Portfolio

Track Prospera Financial Services Inc Portfolio

Follow Prospera Financial Services Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prospera Financial Services Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prospera Financial Services Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email